- Acumen Powered by Robins Kaplan LLP™
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
July 21, 2021Benchmark Litigation Names Patrick Arenz and Aaron Fahrenkrog to its 40 & Under Hot List in 2021
-
July 20, 2021Five Robins Kaplan Firm Members Recognized by Minnesota Lawyer
-
July 19, 2021Robins Kaplan Attorneys Recognized as 2021 Minnesota Super Lawyers and Rising Stars
-
July 26, 2021Tee It up for the Troops
-
August 5, 2021Domesticating an Out of State Judgment in The State of Florida
-
August 6, 2021Mastering the Deposition: 30(b)(6) Deposition Strategies and Updates 2021
-
July 15, 2021Biotechnology & Trade Secret Protection
-
July 6, 2021'Abuse of dominance': Was this what Congress originally intended for Section 2?
-
Summer 2021Family Feud: A Cautionary Tale of the Costs, Risks, and Uncertainty of Minority-Shareholder Litigation
-
July 23, 2021Financial Daily Dose 7.23.2021 | Top Story: Amazon Abruptly Drops Mandatory Arbitration Requirement
-
July 22, 2021Financial Daily Dose 7.22.2021 | Top Story: Drug Companies Strike $26B Deal with State AGs Over Opioid Crisis
-
July 21, 2021Financial Daily Dose 7.21.2021 | Top Story: White House Names Google Critic Kanter to Lead DOJ Antitrust Division
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
5 Takeaways from FDAs Draft Guidance
March 21, 2016
Read the full article (MDDI DeviceTalk) >
Data are becoming an increasingly integral component of medical technologies, including medical devices. However, the sensitive nature of healthcare data increases the risk that device companies and their partners will be targets of cyberattacks and heightens the consequences of a breach.
The FDA’s guidance doesn't cover all regulatory risks related to cyberattacks and provides no safe harbor for device makers.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
MDDI DeviceTalk
Related Professionals
Ryan W. Marth
Partner
Richard Martinez
Related Publications
April 2, 2021
Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
Michael Reif, Akina Khan - Law360
August 19, 2019
April 2018
Safeguarding Information Theft by Departing Employees
Industry Today
July 10, 2017
February 21, 2017
Related News
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.